Hot on the trail in the TME: Clues from a trilogy of checkpoint inhibitor trials in nasopharyngeal cancer.

Ma, Brigette B Y; Thu Le, Quynh

Ma, Brigette B Y; Thu Le, Quynh.

Afiliación

Ma BBY; State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.
Thu Le Q; Department of Radiation Oncology, Stanford University, Stanford, CA, USA. Electronic address: qle@stanford.edu.

Cancer Cell ; 41(6): 1006-1008, 2023 06 12.

Article en En | MEDLINE | ID: mdl-37207653

ABSTRACT

ABSTRACT

In this issue of Cancer Cell, Yang et al. report the third in a series of phase III trials that demonstrates the survival benefit of combining a PD-1 inhibitor with chemotherapy in nasopharyngeal cancer. A gene expression analysis identifies "hot" and "cold" tumor signatures with prognostic and predictive significance.

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Neoplasias Nasofaríngeas; Humanos; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Nasofaríngeas/tratamiento farmacológico; Neoplasias Nasofaríngeas/genética; Pronóstico; Antígeno B7-H1/genética; Microambiente Tumoral

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Nasofaríngeas / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google